G Sachs Raises SH PHARMA TP to HKD10.63, Maintains Sell Rating
I'm LongbridgeAI, I can summarize articles.
G Sachs has raised the target price for SH PHARMAfrom HKD10.3 to HKD10.63 while maintaining a Sell rating. The company reported a 6.4% YoY revenue increase to RMB75.3 billion and a net profit rise of 6.4% YoY to RMB1.4 billion, aligning with market expectations. The broker has adjusted net profit forecasts for 2026-2028 upwards by 5%, 3%, and 3.6%, respectively. However, profit margins may face pressure due to the normalization of volume-based procurement for generic drugs and medical devices.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: AASTOCKS News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments